<p>Tema Etfs LLC 在最近向證券交易委員會（SEC）提交的文件中表示，在第二季度將其在 Syndax Pharmaceuticals, Inc.（NASDAQ:SNDX - 免費報告）的股份增加了 307.7%。該機構投資者在本季度額外收購了 65,132 股後，持有該公司 86,301 股股票。Tema Etfs LLC 在最近一個季度末持有 Syndax Pharmaceuticals 約 0.10% 的股份，價值 808,000 美元。</p>
<p>獲取 <strong>Syndax Pharmaceuticals</strong> 的提醒：</p>
<p>其他大型投資者最近也買賣了該公司的股票。富蘭克林資源公司在第二季度將其在 Syndax Pharmaceuticals 的股份增加了 14.5%。富蘭克林資源公司現在擁有 2,359,677 股該公司的股票，價值 22,098,000 美元，此前在上個季度額外購買了 298,272 股。Geode Capital Management LLC 在第二季度將其在 Syndax Pharmaceuticals 的股份增加了 1.3%。Geode Capital Management LLC 現在擁有 2,049,350 股該公司的股票，價值 19,195,000 美元，此前在此期間額外購買了 26,365 股。Aisling Capital Management LP 在第二季度將其在 Syndax Pharmaceuticals 的股份增加了 28.5%。Aisling Capital Management LP 現在擁有 1,316,806 股該公司的股票，價值 12,325,000 美元，此前在上個季度額外購買了 291,806 股。Algert Global LLC 在第一季度將其在 Syndax Pharmaceuticals 的持股增加了 12.6%。Algert Global LLC 現在擁有 884,600 股該公司的股票，價值 10,867,000 美元，此前在此期間額外收購了 98,968 股。最後，Candriam S.C.A. 在第二季度將其在 Syndax Pharmaceuticals 的持股增加了 49.9%。Candriam S.C.A. 現在擁有 675,085 股該公司的股票，價值 6,322,000 美元，此前在此期間額外收購了 224,650 股。</p>
<h2>Syndax Pharmaceuticals 股票上漲 2.9%</h2>
<p>SNDX 週五開盤價為 20.32 美元。該公司的債務與股本比率為 2.78，流動比率為 4.64，速動比率為 4.42。Syndax Pharmaceuticals, Inc. 的 12 個月最低價為 8.58 美元，最高價為 20.59 美元。該股票的市值為 17.7 億美元，市盈率為 -5.63，貝塔值為 0.48。該公司的 50 日簡單移動平均線為 16.30 美元，200 日簡單移動平均線為 13.57 美元。</p>
<p>Syndax Pharmaceuticals（NASDAQ:SNDX - 獲取免費報告）上次發佈季度財報是在 11 月 3 日星期一。該公司報告的每股收益（EPS）為（0.70）美元，超過了市場共識預期的（0.74）美元，超出 0.04 美元。該公司在本季度的收入為 4587 萬美元，而分析師預期為 4908 萬美元。Syndax Pharmaceuticals 的股本回報率為 -160.60%，淨利潤率為 -279.31%。與去年同期相比，Syndax Pharmaceuticals 的收入增長了 266.4%。在去年同期，該公司每股收益為（0.98）美元。平均而言，股票分析師預計 Syndax Pharmaceuticals, Inc. 在當前財政年度的每股收益將為 -3.72 美元。</p>
<h2>華爾街分析師預測增長</h2>
<p>幾家研究公司最近對 SNDX 進行了評論。巴克萊將 Syndax Pharmaceuticals 的股票目標價從 22.00 美元上調至 35.00 美元，並在 11 月 24 日的研究報告中給予該公司 “增持” 評級。高盛集團將 Syndax Pharmaceuticals 的股票目標價從 20.00 美元上調至 24.00 美元，並在 9 月 5 日的報告中給予該公司 “買入” 評級。韋斯評級在週一的研究報告中重申了對 Syndax Pharmaceuticals 的 “賣出（d-）” 評級。斯蒂費爾·尼古拉斯在 9 月 10 日的研究報告中啓動了對 Syndax Pharmaceuticals 的覆蓋。他們給予該股票 “買入” 評級，並設定了 44.00 美元的目標價。最後，華爾街 Zen 在週六的研究報告中將 Syndax Pharmaceuticals 的評級從 “持有” 下調至 “賣出”。一位研究分析師對該股票給予了強烈買入評級，九位分析師給予了買入評級，一位分析師給予了持有評級，一位分析師給予了賣出評級。根據 MarketBeat 的數據，Syndax Pharmaceuticals 目前的共識評級為 “適度買入”，平均目標價為 37.20 美元。</p>
<p><strong>閲讀我們最新的 SNDX 股票分析</strong></p>
<h2>內部人士下注</h2>
<p>在其他新聞中，首席執行官 Michael A. Metzger 在 9 月 8 日星期一出售了 157,307 股該公司的股票。該股票以平均價格 16.41 美元出售，總交易額為 2,581,407.87 美元。出售後，首席執行官持有 298,661 股該公司的股票，價值 4,901,027.01 美元。此次交易使其持股減少了 34.50%。該交易已在向證券交易委員會的法律文件中披露，相關文件可通過此鏈接獲取。內部人士持有該公司 4.10% 的股份。</p>
<h2>Syndax Pharmaceuticals 簡介</h2>
<p>（免費報告）</p>
<p>Syndax Pharmaceuticals, Inc. 是一家臨牀階段的生物製藥公司，開發用於癌症治療的療法。其主要產品候選藥物包括 revumenib，一種強效、選擇性的、針對 menin-MLL 結合相互作用的小分子抑制劑，用於治療 KMT2A 重排的急性白血病和實體瘤；以及 SNDX-6352 或 axatilimab，一種單克隆抗體，阻斷集落刺激因子 1（CSF-1）受體，用於治療慢性移植物抗宿主病（cGVHD）和特發性肺纖維化（IPF）患者。</p>
<h2>瞭解更多</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Syndax Pharmaceuticals</li>
<li>NYSE 股票為投資者提供多種優質選擇</li>
<li>比爾和梅琳達·蓋茨基金會出售 MSFT 股票——投資者應該擔心嗎？</li>
<li>高飛者：2022 年 3 月的 3 只天然氣股票</li>
<li>MarketBeat 週迴顧 – 12/1 - 12/5</li>
<li>深入瞭解買賣差價</li>
<li>Rocket Lab 的大反彈？分析師建議此次下跌是個機會</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05EWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05EWA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Syndax Pharmaceuticals 嗎？</h2>
<p>在你考慮 Syndax Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Syndax Pharmaceuticals 並不在名單上。</p>
<p>雖然 Syndax Pharmaceuticals 目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Syndax制藥

<p>Tema Etfs LLC 在第二季度將其在 Syndax Pharmaceuticals 的股份增加了 307.7%，持有 86,301 股，價值 808,000 美元。其他投資者也增加了他們的持股。Syndax 的股票上漲了 2.9%，市值為 17.7 億美元。分析師的評級不一，普遍共識為 “適度買入”，平均目標價為 37.20 美元。首席執行官 Michael Metzger 出售了價值 258 萬美元的股份</p>

<p>Tema Etfs LLC increased its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 307.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 86,301 shares of the company's stock after acquiring an additional 65,132 shares during the quarter. Tema Etfs LLC owned about 0.10% of Syndax Pharmaceuticals worth $808,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Tema Etfs LLC 在最近向證券交易委員會（SEC）提交的文件中表示，在第二季度將其在 Syndax Pharmaceuticals, Inc.（NASDAQ:SNDX - 免費報告）的股份增加了 307.7%。該機構投資者在本季度額外收購了 65,132 股後，持有該公司 86,301 股股票。Tema Etfs LLC 在最近一個季度末持有 Syndax Pharmaceuticals 約 0.10% 的股份，價值 808,000 美元。</p>
</div><p>Get <strong>Syndax Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Syndax Pharmaceuticals</strong> 的提醒：</p>
</div><p>Other large investors also recently bought and sold shares of the company. Franklin Resources Inc. increased its position in shares of Syndax Pharmaceuticals by 14.5% during the second quarter. Franklin Resources Inc. now owns 2,359,677 shares of the company's stock worth $22,098,000 after purchasing an additional 298,272 shares in the last quarter. Geode Capital Management LLC increased its position in Syndax Pharmaceuticals by 1.3% during the second quarter. Geode Capital Management LLC now owns 2,049,350 shares of the company's stock worth $19,195,000 after buying an additional 26,365 shares during the period. Aisling Capital Management LP lifted its stake in Syndax Pharmaceuticals by 28.5% in the second quarter. Aisling Capital Management LP now owns 1,316,806 shares of the company's stock valued at $12,325,000 after buying an additional 291,806 shares during the last quarter. Algert Global LLC boosted its holdings in shares of Syndax Pharmaceuticals by 12.6% in the first quarter. Algert Global LLC now owns 884,600 shares of the company's stock valued at $10,867,000 after acquiring an additional 98,968 shares during the period. Finally, Candriam S.C.A. boosted its holdings in shares of Syndax Pharmaceuticals by 49.9% in the second quarter. Candriam S.C.A. now owns 675,085 shares of the company's stock valued at $6,322,000 after acquiring an additional 224,650 shares during the period.</p>
<div class="lb-trans"><p>其他大型投資者最近也買賣了該公司的股票。富蘭克林資源公司在第二季度將其在 Syndax Pharmaceuticals 的股份增加了 14.5%。富蘭克林資源公司現在擁有 2,359,677 股該公司的股票，價值 22,098,000 美元，此前在上個季度額外購買了 298,272 股。Geode Capital Management LLC 在第二季度將其在 Syndax Pharmaceuticals 的股份增加了 1.3%。Geode Capital Management LLC 現在擁有 2,049,350 股該公司的股票，價值 19,195,000 美元，此前在此期間額外購買了 26,365 股。Aisling Capital Management LP 在第二季度將其在 Syndax Pharmaceuticals 的股份增加了 28.5%。Aisling Capital Management LP 現在擁有 1,316,806 股該公司的股票，價值 12,325,000 美元，此前在上個季度額外購買了 291,806 股。Algert Global LLC 在第一季度將其在 Syndax Pharmaceuticals 的持股增加了 12.6%。Algert Global LLC 現在擁有 884,600 股該公司的股票，價值 10,867,000 美元，此前在此期間額外收購了 98,968 股。最後，Candriam S.C.A. 在第二季度將其在 Syndax Pharmaceuticals 的持股增加了 49.9%。Candriam S.C.A. 現在擁有 675,085 股該公司的股票，價值 6,322,000 美元，此前在此期間額外收購了 224,650 股。</p>
</div><h2>Syndax Pharmaceuticals Stock Up 2.9%</h2>
<div class="lb-trans"><h2>Syndax Pharmaceuticals 股票上漲 2.9%</h2>
</div><p>SNDX opened at $20.32 on Friday. The company has a debt-to-equity ratio of 2.78, a current ratio of 4.64 and a quick ratio of 4.42. Syndax Pharmaceuticals, Inc. has a 12 month low of $8.58 and a 12 month high of $20.59. The stock has a market capitalization of $1.77 billion, a P/E ratio of -5.63 and a beta of 0.48. The business has a 50 day simple moving average of $16.30 and a 200-day simple moving average of $13.57.</p>
<div class="lb-trans"><p>SNDX 週五開盤價為 20.32 美元。該公司的債務與股本比率為 2.78，流動比率為 4.64，速動比率為 4.42。Syndax Pharmaceuticals, Inc. 的 12 個月最低價為 8.58 美元，最高價為 20.59 美元。該股票的市值為 17.7 億美元，市盈率為 -5.63，貝塔值為 0.48。該公司的 50 日簡單移動平均線為 16.30 美元，200 日簡單移動平均線為 13.57 美元。</p>
</div><p>Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its quarterly earnings data on Monday, November 3rd. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.04. The firm had revenue of $45.87 million during the quarter, compared to analysts' expectations of $49.08 million. Syndax Pharmaceuticals had a negative return on equity of 160.60% and a negative net margin of 279.31%.Syndax Pharmaceuticals's revenue was up 266.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.98) earnings per share. On average, equities analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Syndax Pharmaceuticals（NASDAQ:SNDX - 獲取免費報告）上次發佈季度財報是在 11 月 3 日星期一。該公司報告的每股收益（EPS）為（0.70）美元，超過了市場共識預期的（0.74）美元，超出 0.04 美元。該公司在本季度的收入為 4587 萬美元，而分析師預期為 4908 萬美元。Syndax Pharmaceuticals 的股本回報率為 -160.60%，淨利潤率為 -279.31%。與去年同期相比，Syndax Pharmaceuticals 的收入增長了 266.4%。在去年同期，該公司每股收益為（0.98）美元。平均而言，股票分析師預計 Syndax Pharmaceuticals, Inc. 在當前財政年度的每股收益將為 -3.72 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>Several research firms recently commented on SNDX. Barclays upped their price target on shares of Syndax Pharmaceuticals from $22.00 to $35.00 and gave the company an &#34;overweight&#34; rating in a research report on Monday, November 24th. The Goldman Sachs Group upped their target price on shares of Syndax Pharmaceuticals from $20.00 to $24.00 and gave the company a &#34;buy&#34; rating in a report on Friday, September 5th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Syndax Pharmaceuticals in a research note on Monday. Stifel Nicolaus initiated coverage on Syndax Pharmaceuticals in a research report on Wednesday, September 10th. They issued a &#34;buy&#34; rating and a $44.00 price target on the stock. Finally, Wall Street Zen cut Syndax Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Syndax Pharmaceuticals currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $37.20.</p>
<div class="lb-trans"><p>幾家研究公司最近對 SNDX 進行了評論。巴克萊將 Syndax Pharmaceuticals 的股票目標價從 22.00 美元上調至 35.00 美元，並在 11 月 24 日的研究報告中給予該公司 “增持” 評級。高盛集團將 Syndax Pharmaceuticals 的股票目標價從 20.00 美元上調至 24.00 美元，並在 9 月 5 日的報告中給予該公司 “買入” 評級。韋斯評級在週一的研究報告中重申了對 Syndax Pharmaceuticals 的 “賣出（d-）” 評級。斯蒂費爾·尼古拉斯在 9 月 10 日的研究報告中啓動了對 Syndax Pharmaceuticals 的覆蓋。他們給予該股票 “買入” 評級，並設定了 44.00 美元的目標價。最後，華爾街 Zen 在週六的研究報告中將 Syndax Pharmaceuticals 的評級從 “持有” 下調至 “賣出”。一位研究分析師對該股票給予了強烈買入評級，九位分析師給予了買入評級，一位分析師給予了持有評級，一位分析師給予了賣出評級。根據 MarketBeat 的數據，Syndax Pharmaceuticals 目前的共識評級為 “適度買入”，平均目標價為 37.20 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on SNDX</strong></p>
<div class="lb-trans"><p><strong>閲讀我們最新的 SNDX 股票分析</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><p>In other news, CEO Michael A. Metzger sold 157,307 shares of the business's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $16.41, for a total transaction of $2,581,407.87. Following the sale, the chief executive officer owned 298,661 shares of the company's stock, valued at $4,901,027.01. The trade was a 34.50% decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. Insiders own 4.10% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，首席執行官 Michael A. Metzger 在 9 月 8 日星期一出售了 157,307 股該公司的股票。該股票以平均價格 16.41 美元出售，總交易額為 2,581,407.87 美元。出售後，首席執行官持有 298,661 股該公司的股票，價值 4,901,027.01 美元。此次交易使其持股減少了 34.50%。該交易已在向證券交易委員會的法律文件中披露，相關文件可通過此鏈接獲取。內部人士持有該公司 4.10% 的股份。</p>
</div><h2>Syndax Pharmaceuticals Profile</h2>
<div class="lb-trans"><h2>Syndax Pharmaceuticals 簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).</p>
<div class="lb-trans"><p>Syndax Pharmaceuticals, Inc. 是一家臨牀階段的生物製藥公司，開發用於癌症治療的療法。其主要產品候選藥物包括 revumenib，一種強效、選擇性的、針對 menin-MLL 結合相互作用的小分子抑制劑，用於治療 KMT2A 重排的急性白血病和實體瘤；以及 SNDX-6352 或 axatilimab，一種單克隆抗體，阻斷集落刺激因子 1（CSF-1）受體，用於治療慢性移植物抗宿主病（cGVHD）和特發性肺纖維化（IPF）患者。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Syndax Pharmaceuticals</li>
<li>NYSE Stocks Give Investors a Variety of Quality Options</li>
<li>Gates Foundation Sells MSFT Stock—Should Investors Be Worried?</li>
<li>High Flyers: 3 Natural Gas Stocks for March 2022</li>
<li>MarketBeat Week in Review – 12/1 - 12/5</li>
<li>A Deeper Look at Bid-Ask Spreads</li>
<li>Rocket Lab’s Big Rebound? Analysts Suggest the Dip's a Gift</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Syndax Pharmaceuticals</li>
<li>NYSE 股票為投資者提供多種優質選擇</li>
<li>比爾和梅琳達·蓋茨基金會出售 MSFT 股票——投資者應該擔心嗎？</li>
<li>高飛者：2022 年 3 月的 3 只天然氣股票</li>
<li>MarketBeat 週迴顧 – 12/1 - 12/5</li>
<li>深入瞭解買賣差價</li>
<li>Rocket Lab 的大反彈？分析師建議此次下跌是個機會</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05EWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=SNDX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Syndax Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Syndax Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Syndax Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Syndax Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Syndax Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Syndax Pharmaceuticals 並不在名單上。</p>
</div><p>While Syndax Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Syndax Pharmaceuticals 目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Syndax 製藥公司 $SNDX 的股票被 Tema Etfs LLC 收購